An observational study in Metastatic Colorectal Cancer, sponsored by Libbs Farmacêutica LTDA. Recruiting at 14 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Libbs Farmacêutica LTDA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Colorectal Neoplasms with a site in Brazil — 18 open to participants now, 27 under way, 12 of them phase 3. Colorectal Neoplasms · Brazil.
Among the 79 studies in Colorectal Neoplasms with a site in Brazil, this one is one of 7 that started in 2025, is one of 7 observational ones, reaches primary completion later than 11 of the 26 other live ones, and was the 68th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →18 of the 79 studies in Colorectal Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:
AbbVie · Sites in Brazil, United States, Belgium and 8 more countries
Ages 18+
Incyte Corporation · Sites in Brazil, United States, Argentina and 19 more countries
Ages 18+
Faculdade de Ciências Médicas de Minas Gerais · Sites in Brazil
Ages 18–80
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 22 more countries
Ages 18+
Pfizer · Sites in Brazil, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 35 · Phase 4 1
First in 1998; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 133 is below the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 392 across the 71 interventional studies, 240 across the 7 observational. Of the 39 that completed or were terminated, 21 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 79 have an industry lead sponsor. The 10 most frequent:
Libbs Farmacêutica LTDA is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Libbs Farmacêutica LTDA has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Colorectal Neoplasms with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02185443University of Sao PauloStereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases | 2026-12 |
| NCT07388953Faculdade de Ciências Médicas de Minas GeraisPeripheral Autonomic Block (BAP) Plus Transversus Abdominis Plane Block (TAP) for Postoperative Analgesia After Minimally Invasive Left-Sided Colorectal Resection (BAPTAP) | 2026-12-05 |
| NCT07797361Alexandre Vontobel PadoinEvaluation of Versatile Intelligent Staining Technology (VIST) and Spectral Flexible Imaging (SFI) for Detection and Optical Characterization of Colorectal Lesions: A Prospective Randomized Controlled Study | 2027-01-31 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
| NCT07268846AC Camargo Cancer CenterUse of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery | 2027-06-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 79 studies in Colorectal Neoplasms with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal cancer is one of the most common tumors and is the second most prevalent cause of cancer death, leading to almost 1 million deaths per year.Elovie is a bevacizumab biosimilar medicine marketed by Libbs Farmacêutica, which had its registration approved by ANVISA in May 2022.At the time of registration a robust evidence package was presented that included, for example, pharmacokinetic bioequivalence studies in patients with metastatic RCC (mRCC) and a phase III study in participants with non-small cell lung cancer .Conducting a real-world study to evaluate the effectiveness and safety of bevacizumab biosimilar Elovie in patients with mCRC is crucial to provide relevant information on how this therapy behaves in real-world clinical conditions in brazilian population.
Observational, multicenter study with real-world data from specialized cancer centers in Brazil. Participants over 18 years of age, of both sexes, with unresectable clinical stage IV metastatic colorectal cancer, who have received Elovie® (bevacizumab biosimilar) at participating centers and who meet the eligibility criteria will be invited to participate. In this study, data on the effectiveness and safety of treatment with Elovie, as well as clinical and demographic characteristics and treatment patterns will be collected.
Participants will undergo standard treatment and clinical follow-up as determined by the treating physician.
Data collection will be performed by the researcher and the data transcribed into the Case Report Form data collection form designed specifically for the study.
Adult participants of both sexes diagnosed with metastatic colorectal cancer, clinical stage IV unresectable, by clinical definition in medical records, according to the investigator's assessment at the initial consultation and before any type of palliative treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluate the effectiveness of treatment with bevacizumab
Median duration in months and number of cycles of first-line treatment until the switch to second-line treatment, for any reason, through the collection of electronic medical record data.
Time frame: 24 months
progression-free survival
progression-free survival will be defined as the median time (in months) from the first dose of bevacizumab to disease progression
Time frame: 24 months
Overall survival
Overall survival will be defined as the median time (in months) from the first dose of bevacizumab until the occurrence of death, from any cause, during the 24-month follow-up period
Time frame: 24 months
The survival rate
The survival rate will be defined as the number and proportion of participants who remained alive after 24 months of follow-up
Time frame: 24 months
Objective Response Rate
The Objective Response Rate will be defined as the number and percentage of participants who had a Complete Response or Partial Response, using the usual methodology of the research center, during 24 months of follow-up after the start of bevacizumab use. The number and percentage of participants who had Stable Disease or Disease Progression will also be evaluated.
Time frame: 24 months
Functional capacity
Functional capacity will be assessed using the ECOG (Eastern cooperative oncology group) scale during 24 months of follow-up after starting bevacizumab. Scale ECOG Grade 0 - Fully active, able to carry on all pre disease performance without restriction Grade 1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work Grade 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours Grade 3 - Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours Grade 4 - Completely disabled; cannot carry on any selfcare; totally confined to bed or chair Grade 5 - Dead https://ecog-acrin.org/resources/ecog-performance-status/
Time frame: 24 months
Safety assessment
To assess the occurrence of adverse events in the 24-month follow-up period since the first dose of Elovie.Assess the median duration of treatment through time in months and number of cycles until switching to another treatment other than the first line, for reasons of toxicity (adverse event).
Time frame: 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 29 months after the start.
Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 29 months is below that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Libbs Farmacêutica LTDA